Image by torstensimon from Pixabay
In the midst of figuring out scaling and storage of current COVID-19 vaccinations, it’s important for researchers to continue developing additional vaccines.
Toward that end, Michigan State University is making its way through its Phase 1 clinical trial using a vector platform developed by Andrea Amalfitano, dean of the College of Osteopathic Medicine.
The researchers remove the genetic information that causes a cold, leaving a virus that can be used as a genetic delivery platform, also known as a vector platform.
While the tech was originally designed to improve the safety of gene therapy, Amalfitano discovered that the vector can also be used in a “plug-and-play” manner to treat a variety of infectious diseases.
Since the vector platform is not an RNA-based vaccine, it would be much easier to scale up production.